Central Retinal Vein Occlusion: The Effect of Antiplatelet and Anticoagulant Agents

Abstract

Purpose:

This work evaluates the effect of antiplatelet and anticoagulant agents on clinical outcomes, optical coherence tomography (OCT) parameters, and macular ischemia in eyes with central retinal vein occlusion (CRVO).

Methods:

A retrospective longitudinal cohort study was performed to evaluate patients with CRVO. Demographics, OCT parameters before and after treatment, macular ischemia on fluorescein angiography, and clinical outcomes including the number of injections received were analyzed.

Results:

A total of 365 patients with CRVO were identified. The average follow-up was 36 months. Antiplatelet or anticoagulant agent use was not associated with a significant difference in visual acuity (VA), prevalence of macular edema, or central subfield thickness on OCT at presentation or final visit. The use of 81-mg aspirin alone was associated with an increased prevalence of foveal hemorrhage at presentation. Patients who were taking an antiplatelet agent, an anticoagulation agent, or both and had an ischemic CRVO with logMAR VA of less than 1.0 experienced improved VA at the final study visit. Patients given antiplatelet or anticoagulant agents had a similar incidence of neovascular sequelae compared with patients not administered these agents.

Conclusions:

In eyes with CRVO, the use of antiplatelet or anticoagulant agents at CRVO onset was not associated with significantly different functional outcomes, except in ischemic CRVO eyes with VA of less than 20/200. The use of 81-mg aspirin was associated with foveal hemorrhage at CRVO presentation. Otherwise, the use of any antiplatelet agent or anticoagulation was not associated with any CRVO structural outcomes.

Keywords

anticoagulation antiplatelet agents central retinal vein occlusion fluorescein angiography optical coherence tomography

Get full access to this article

View all access options for this article.

References

Chen

Vargas-Bustamante

Mortensen

Ortega

. Racial and ethnic disparities in health care access and utilization under the affordable care act. Med Care. 2016;54(2):140–146. doi:10.1097/mlr.0000000000000467

Cheung

Klein

Wang

, et al. Traditional and novel cardiovascular risk factors for retinal vein occlusion: the multiethnic study of atherosclerosis. Invest Ophthalmol Visual Sci. 2008;49(10):4297–4302. doi:10.1167/iovs.08-1826

Chobanian

Bakris

Black

, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560–2572. doi:10.1001/jama.289.19.2560

Cugati

Wang

Rochtchina

Mitchell

. Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol. 2006;124(5):726–732. doi:10.1001/archopht.124.5.726

Wong

Larsen

EKM

Klein

, et al. Cardiovascular risk factors for retinal vein occlusion and arteriolar emboli: the Atherosclerosis Risk in Communities & Cardiovascular Health studies. Ophthalmology. 2005;112(4):540–547. doi:10.1016/j.ophtha.2004.10.039

Wong

Scott

. Clinical practice. Retinal-vein occlusion. N Eng J Med. 2010;363(22):2135–2144. doi:10.1056/NEJMcp1003934

Ehlers

Fekrat

. Retinal vein occlusion: beyond the acute event. Survey Ophthalmol. 2011;56(4):281–299. doi:10.1016/j.survophthal.2010.11.006

Hayreh

. Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res. 2005;24(4):493–519. doi:10.1016/j.preteyeres.2004.12.001

Hayreh

Podhajsky

Zimmerman

. Central and hemicentral retinal vein occlusion: role of anti-platelet aggregation agents and anticoagulants. Ophthalmology. 2011;118(8):1603–1611. doi:10.1016/j.ophtha.2011.04.036

10.

Klein

Moss

Meuer

. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc. 2000;98:133–141; discussion 141-143.

11.

Mitchell

Smith

Chang

. Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol. 1996;114(10):1243–1247. doi:10.1001/archopht.1996.01100140443012

12.

Mir

Thomas

Yoon

Birnbaum

Goerlitz-Jessen

Fekrat

. Eyes with acute, treatment-naïve CRVO and foveal intraretinal hemorrhage: characteristics and outcomes. Ophthalmic Surg Lasers Imaging Retina. 2019;50(12):752–759. doi:10.3928/23258160-20191119-02

13.

Squizzato

Manfredi

Bozzato

Dentali

Ageno

. Antithrombotic and fibrinolytic drugs for retinal vein occlusion: a systematic review and a call for action. Thrombosis & Haemostasis. 2010;103(2):271-6. doi:10.1160/TH09-09-0626

14.

Arnett

Blumenthal

Albert

, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;74(10):e177–e232. doi:10.1016/j.jacc.2019.03.010

15.

Ageno

Cattaneo

Manfredi

, et al. Parnaparin versus aspirin in the treatment of retinal vein occlusion. A randomized, double blind, controlled study. Thromb Res. 2010;125(2):137–141. doi:10.1016/j.thromres.2009.05.007

16.

Lazo-Langner

Hawel

Ageno

Kovacs

. Low molecular weight heparin for the treatment of retinal vein occlusion: a systematic review and meta-analysis of randomized trials. Haematologica. 2010;95(9):1587–1593. doi:10.3324/haematol.2010.023614

17.

Kiew

Thomas

Fekrat

. Characteristics of central retinal vein occlusion in African Americans. J Vitreoretin Dis. 2020;4(3):186–191. doi:10.1177/2474126419882829